Osmotica Pharmaceuticals plc (OSMT) Misses Q1 EPS by 10c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. PINS
4. COIN
5. RDDT
6. FSLR
7. FND
8. SYK
9. GILD
10. SNDK

Go back to Osmotica Pharmaceuticals plc (OSMT) Misses Q1 EPS by 10c, Revenues Miss

Osmotica Pharmaceuticals plc Reports Second Quarter 2020 Results and Provides Business Updates

August 11, 2020 4:06 PM EDT

Second quarter 2020 total revenue of $37.5 million

Received U.S Food and Drug Administration (FDA) approval for Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1% for acquired blepharoptosis (ptosis or droopy eyelid) in adults

Entered into exclusive license agreement with Santen Pharmaceutical Co. Ltd. in Japan, Asia and EMEA for RVL-1201 (Upneeq)

User fee goal date of December 29, 2020 set by FDA for arbaclofen extended release (ER) tablets for spasticity in Multiple Sclerosis patients

BRIDGEWATER, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT)... More